8329 — Shenzhen Neptunus Interlong Bio-technique Co Share Price
- HK$261.77m
- HK$62.26m
- CNY1.06bn
- 54
- 98
- 50
- 81
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.27 | ||
Price to Tang. Book | 0.34 | ||
Price to Free Cashflow | 6.32 | ||
Price to Sales | 0.23 | ||
EV to EBITDA | 0.91 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 3.45% | ||
Return on Equity | 2.69% | ||
Operating Margin | 3.4% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 1,080.87 | 1,031.37 | 838.8 | 986.69 | 1,064.86 | n/a | n/a | 4.19% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +30.01 | -15.74 | -32.4 | +57.65 | -42.19 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Shenzhen Neptunus Interlong Bio-Technique Company Limited is a Hong Kong-based company principally engaged in the development, production and sales of medicines. The Company operates through three segments. Medicines segment is engaged in the manufacture and sales of medicines. Medicines and Healthcare Products segment is engaged in the sales and distribution of medicines and healthcare products. Research and Development Services of Modern Biological Technology segment is engaged in the provision of research and development services of modern biological technologies, such as in vitro diagnostics reagents businesses. The products of the Company include herbal medicines, generic drugs, transfusion and anti-tumor drugs, among others. The Company mainly operates businesses in China.
Directors
- Feng Zhang CHM
- Jian Bo Huang GMG (44)
- Man Chao Wang OTH (37)
- Hang Yuan OTH (39)
- Wai Sum Fung SEC
- Ling Xia Mu SEC (46)
- Zhanjun Liu NED
- Ting Jiu Song NED (59)
- Yan He Xu NED (59)
- Lin Yu NED (58)
- Yi Fei Zhang NED (48)
- Wen Liang Zhao NED (40)
- Ka Yeung Poon NID (50)
- Wing Fat Yick NID (62)
- Jian Zhou Zhang NID (46)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 15th, 1994
- Public Since
- September 12th, 2005
- No. of Employees
- 1,444
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,678,000,000
- Address
- 1F, Block 1, Research Building, SHENZHEN, 518000
- Web
- https://www.interlong.com/
- Phone
- +86 75526411869
- Auditors
- Grant Thornton Hong Kong Limited
Upcoming Events for 8329
Shenzhen Neptunus Interlong Bio-technique Co Ltd Annual Shareholders Meeting
Q2 2024 Shenzhen Neptunus Interlong Bio-technique Co Ltd Earnings Release
Similar to 8329
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:15 UTC, shares in Shenzhen Neptunus Interlong Bio-technique Co are trading at HK$0.16. This share price information is delayed by 15 minutes.
Shares in Shenzhen Neptunus Interlong Bio-technique Co last closed at HK$0.16 and the price had moved by +5.41% over the past 365 days. In terms of relative price strength the Shenzhen Neptunus Interlong Bio-technique Co share price has outperformed the FTSE Developed Asia Pacific Index by +5.51% over the past year.
There is no consensus recommendation for this security.
Shenzhen Neptunus Interlong Bio-technique Co does not currently pay a dividend.
Shenzhen Neptunus Interlong Bio-technique Co does not currently pay a dividend.
Shenzhen Neptunus Interlong Bio-technique Co does not currently pay a dividend.
To buy shares in Shenzhen Neptunus Interlong Bio-technique Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.16, shares in Shenzhen Neptunus Interlong Bio-technique Co had a market capitalisation of HK$261.77m.
Here are the trading details for Shenzhen Neptunus Interlong Bio-technique Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 8329
Based on an overall assessment of its quality, value and momentum Shenzhen Neptunus Interlong Bio-technique Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shenzhen Neptunus Interlong Bio-technique Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -14.45%.
As of the last closing price of HK$0.16, shares in Shenzhen Neptunus Interlong Bio-technique Co were trading -1.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shenzhen Neptunus Interlong Bio-technique Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shenzhen Neptunus Interlong Bio-technique Co's management team is headed by:
- Feng Zhang - CHM
- Jian Bo Huang - GMG
- Man Chao Wang - OTH
- Hang Yuan - OTH
- Wai Sum Fung - SEC
- Ling Xia Mu - SEC
- Zhanjun Liu - NED
- Ting Jiu Song - NED
- Yan He Xu - NED
- Lin Yu - NED
- Yi Fei Zhang - NED
- Wen Liang Zhao - NED
- Ka Yeung Poon - NID
- Wing Fat Yick - NID
- Jian Zhou Zhang - NID